Navigation Links
Shire Delivers Record Quarterly Revenues and Non GAAP Diluted Earnings per ADS up 42%
Date:7/18/2014

2014, compared to significant stocking in Q2 2013.

REPLAGAL - Fabry disease 

REPLAGAL sales were up 14% compared to Q2 2013 as we continue to see good growth in emerging markets and to a lesser extent higher volume demand in Europe. Q2 2014 also benefited from larger bulk orders for Asian markets compared to Q2 2013.

CINRYZE - for the prophylactic treatment of Hereditary Angioedema ("HAE") 

Shire acquired CINRYZE through its acquisition of ViroPharma in Q1 2014, and CINRYZE sales were $129.9 million in Q2 2014. CINRYZE grew 37% on Q2 2013(1)primarily driven by more patients on therapy, a return to standard levels of inventory and to a lesser extent, a price increase in the US.

(1) Q2 2013 recorded by ViroPharma, prior to the acquisition of ViroPharma by Shire.

INTUNIV - ADHD 

The growth in INTUNIV product sales (up 11%) in Q2 2014 was driven by price increases taken since Q2 2013, partially offset by higher sales deductions as a percentage of product sales in Q2 2014.

ADDERALL XR - ADHD 

ADDERALL XR product sales decreased (down 11%) in Q2 2014 primarily due to lower stocking, lower shipments of product to authorised generic suppliers and higher sales deductions in Q2 2014 as compared to Q2 2013.

VPRIV - Gaucher disease 

VPRIV product sales in Q2 2014 were up 9% compared to Q2 2013 as we continue to add naïve patients and gain patients switching from other therapies.

FIRAZYR - for the treatment of acute HAE attacks 

FIRAZYR strong product sales growth (up 80%) was primarily due to growth in patients on therapy, the effect of a price increase and a higher number of treated attacks, particularly in the US market.

PENTASA - Ulcerative Colitis 

PENTASA product sales decreased in Q2 2014 (down 14%) driven by a decrease in US prescription demand and destocking in Q2 2014 as compared to stocking in Q2 2
'/>"/>

SOURCE Shire plc
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc.
2. arGEN-X Receives Two Preclinical Milestone Payments Under Collaboration With Shire
3. Shire Extends Tender Offer for ViroPharma
4. Shire Reports Top-Line Results on OPUS-2, a Phase 3 Study Investigating the Use of Lifitegrast (5.0% Ophthalmic Solution) in Adults With Dry Eye Disease
5. MinuteClinic Opens First Clinic Locations in New Hampshire
6. Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
7. Shire to Present at the Bank of America Merrill Lynch Global Health Care Conference
8. Shire to Present at the Morgan Stanley Global Healthcare Conference
9. Shire Reports 7% Product Sales Growth: Anticipating Double Digit Non GAAP Earnings Growth in 2013
10. Shire Announces Award Recipients for 2013 US ADHD Scholarship Program
11. Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... - Partnership aims to provide convenient access to vaccination ... at work, - "Let,s Fight Flu Together!" initiative ... to 18 years old(1), - Campaign goal is ... for those vaccinated, CAMBRIDGE, Mass., Nov. 10 ...
... Well-Tolerated, Significantly Inhibited ... November 10 at 8:30 ... a.m. ET-, NEW ... a biotechnology company focused on,the development of compounds for the treatment of cardiovascular ...
Cached Medicine Technology:Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 2Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 3Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 4Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 5Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families 'Let's Fight Flu Together!' 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 2VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 3VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 4VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 5VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 6VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 7VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease 8
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences ... sell Arterosil and Arterosil HP, and that all claims and counterclaims have been ... Sciences, LLC (VHS) in the United States District Court for the Southern District ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... The Kentucky ... workers are qualified for the position they are applying for, they are unable to ... many employers are considering altering drug testing policies in order to be able to ...
(Date:8/28/2015)... , ... August 28, 2015 , ... As reported ... Merz, received FDA clearance for results that last for two years, the longest ... news for patients who are looking for a long-lasting, effective solution for their cellulite, ...
(Date:8/28/2015)... ... , ... “ Frequentz ” was featured on NewsWatch as part of its ... market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology ... to track product movement from beginning to end. , Businesses benefit greatly from having ...
(Date:8/28/2015)... Jordan, Utah (PRWEB) , ... August 28, 2015 ... ... been awarded a three-year accreditation for its adolescent residential, counseling, day treatment and ... demonstrates that it meets international standards for quality and its pursuit of excellence. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2
... MedQuist Inc.,(Pink Sheets: MEDQ) announces that it ... Chain Systems, one of the nation,s largest ... and,allowing them to complete the MedQuist suite ... solutions. As partners, MedAssets and MedQuist ...
... 2 Filtrona Fibertec, a division of,Filtrona plc, ... fluid handling components, celebrated the completion,of the recent ... a Grand Opening,celebration. (Logo: http://www.newscom.com/cgi-bin/prnh/20061127/DCM011LOGO ... more than double the size of,production floor space ...
... Oct. 2 Abbott (NYSE: ABT ),announced today ... waived status under the Clinical Laboratory Improvement Amendements,of 1988 ... it,more widely available for use beyond the hospital setting. ... and accurate and,can be made more broadly available to ...
... California, October 2 joimax GmbH, Campbell,CA, is pleased ... Inc. the company is moving to larger premises in ... October 1st, 2007,joimax, Inc. will be located at ... CA 95008 USA "This move reflects the strong ...
... Genetic Engineering and,Biotechnology News, (GEN) first online video ... up by more than 180 media outlets since its,release ... to run on GEN,s,Biotech Video Channel, is a corporate ... the Multimedia News Release, go to:, http://www.prnewswire.com/mnr/gen/29564/ ...
... has added over,6,000 menu items from 70 of ... http://www.NutritionPedia.com, the only online nutrition,search engine. ... content of their favorite menu items available at ... style restaurants such as,Applebee,s Neighborhood Bar and Grill, ...
Cached Medicine News:Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 2Health News:MedQuist and MedAssets Sign Multi-Year Contract for Clinical Documentation Workflow Solutions 3Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge 2Health News:Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge 3Health News:Video: GEN Video Hits Home with Web Audience 2Health News:NutritionPedia Adds Nutrition Facts for Over 6,000 Menu Items From 70 Leading Fast-Casual and Family Dining Restaurant Chains 2
Inquire...
Inquire...
... and optical performance, the SZX7 is designed ... in every task, from routine preparations to ... the best zoom ratios in its class ... color and accurate reproduction of the original ...
... The series SV stereomicroscopes are ... Thanks to their mature modular ... the job in hand. This ... of demanding routine applications will ...
Medicine Products: